SCHEMBL17601907

SCHEMBL17601907

C=CCN(CC(CC)c1cc(=O)oc2cc(O)ccc12)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B3 P37058 9/20 0.44
AKR1B1 P15121 4/20 0.42
LCK P06239 1/20 0.42
FYN P06241 1/20 0.42
GRB2 P62993 1/20 0.42
KDM4E B2RXH2 5/20 0.42
GLA P06280 3/20 0.42
LMNA P02545 3/20 0.42
HPGD P15428 3/20 0.42
CYP1A2 P05177 2/20 0.42
KMT2A Q03164 2/20 0.42
POLB P06746 2/20 0.42
MAPT P10636 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
ALDH1A1 P00352 5/20 0.41
GAA P10253 3/20 0.41
CA12 O43570 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17601899 0.88 AKR1B1 (0.44) HSD17B3AKR1B1LCKFYNGRB2
SCHEMBL17601906 0.82 ERN1 (0.47) KDM4EGLALMNAHPGDMAPT
SCHEMBL28328438 0.80 HSD17B3 (0.63) HSD17B3AKR1B1LCKFYNGRB2
SCHEMBL17601923 0.78 LCK (0.59) HSD17B3AKR1B1LCKFYNGRB2
SCHEMBL17601892 0.75 HSD17B3 (0.55) HSD17B3AKR1B1LCKFYNGRB2
SCHEMBL16197852 0.75 HSD17B3 (0.51) HSD17B3AKR1B1LCKFYNGRB2
SCHEMBL30848862 0.74 ERN1 (0.46) HSD17B3AKR1B1LCKFYNGRB2
SCHEMBL17601894 0.70 ERN1 (0.49) KDM4EGLALMNAHPGDMAPT
SCHEMBL8961041 0.69 HSD17B3 (0.56) HSD17B3AKR1B1LCKFYNGRB2
SCHEMBL29785167 0.68 HSD17B3 (0.63) HSD17B3AKR1B1LCKFYNGRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10323013-B2 Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2019-06-18 US disclosed
US-20160083361-A1 INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2016-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10323013-B2 Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof XBP1, ERN1, SREBF1 HSD17B3 2620/4885AKR1B1 1656/4885LCK 1394/4885
US-20160083361-A1 INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF XBP1, RRP1B, ERN1 HSD17B3 3450/4885AKR1B1 2142/4885LCK 1385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.